Gapping up
In reaction to strong earnings/guidance: RYAAY +4.3%, AZO +1.3%, SKYS +0.4%
M&A news: GKNT +118.6% (to be acquired by Hot Topic for $17.50 per share), LPSN +11.4% (Nice Systems (NICE) takeover speculation), TWC +7.5% (Time Warner Cable confirms it has signed a deal to be acquired by Charter Comm (CHTR) for $195.71/share), CHTR +3.7% (Time Warner Cable confirms it has signed a deal to be acquired by Charter Comm (CHTR) for $195.71/share), EMC +0.9% (to acquire Virtustream, for $1.2 bln in cash)
Other news: IPCI +21% (confirms FDA grants fast track designation for Intellipharmaceutics Rexista Oxycodone XR Incorporating PODRAS Technology), PBMD +10.2% (was up 8%, now lower after releasing press release that is essentially the same press release that was released on 5/19), AEZS +9.3% (announces receipt of advice from the EMA, for the study design of its Phase 3 Study of Macrilen), CERU +9.2% (confirms it has been granted orphan drug designation for CRLX101 for the treatment of ovarian cancer by the FDA), MDR +9.2% (positive Barron's mention/Saudi Aramco contract), CVC +6.1% (following CHTR/TWC deal), ISR +6% (cont volatility), FXCM +4.9% (news Friday afternoon that U.S. & U.K subsidiaries agreed to assume the vast majority of margin forex accounts of CitiFX Pro from Citibank N.A), FOLD +4.9% (confirms that the EMA CHMP has granted Accelerated Assessment for the co's Migalastat HCl monotherapy for Fabry patients), ONTY +3.3% (cont strength), AEGR +3.1% (announces it has achieved the primary endpoint in its Phase III Study of Lomitapide, to treat Homozygous Familial Hypercholesterolemia), PBY +1.8% (Glenhill Advisors discloses 7.0% active stake in 13D filing; to engage in dialogue with co), FEYE +1.6% (favorable commentary on Friday's Mad Money), BLDP +1.4% (receives order for breakthrough technology solutions project with Nisshinbo), JASO +1% (JA Solar and Essel Infraprojects sign MOU to establish a solar cell and module manufacturing facility with 500MW production capacity)
Analyst comments: CTRP +4.3% (target raised to $122 from $80 at Summit Research), BPMC +3.5% (initiated with an Outperform at Cowen), PRTY +1.9% (initiated with a Overweight at Morgan Stanley, initiated with a Overweight at JP Morgan, among others), MRVL +1.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley), LB +1.9% (added to Conviction Buy List at Goldman), BLUE +1.5% (target raised to $213 from $186 at Piper Jaffray), BSM +1.2% (initiated with an Overweight at Barclays), CEO +1.1% (upgraded to Neutral from Underweight at JP Morgan), PANW +1% (target raised to $175 at RBC Capital Mkts), EVA +0.9% (initiated with a Buy at Goldman, among others
)
In reaction to strong earnings/guidance: RYAAY +4.3%, AZO +1.3%, SKYS +0.4%
M&A news: GKNT +118.6% (to be acquired by Hot Topic for $17.50 per share), LPSN +11.4% (Nice Systems (NICE) takeover speculation), TWC +7.5% (Time Warner Cable confirms it has signed a deal to be acquired by Charter Comm (CHTR) for $195.71/share), CHTR +3.7% (Time Warner Cable confirms it has signed a deal to be acquired by Charter Comm (CHTR) for $195.71/share), EMC +0.9% (to acquire Virtustream, for $1.2 bln in cash)
Other news: IPCI +21% (confirms FDA grants fast track designation for Intellipharmaceutics Rexista Oxycodone XR Incorporating PODRAS Technology), PBMD +10.2% (was up 8%, now lower after releasing press release that is essentially the same press release that was released on 5/19), AEZS +9.3% (announces receipt of advice from the EMA, for the study design of its Phase 3 Study of Macrilen), CERU +9.2% (confirms it has been granted orphan drug designation for CRLX101 for the treatment of ovarian cancer by the FDA), MDR +9.2% (positive Barron's mention/Saudi Aramco contract), CVC +6.1% (following CHTR/TWC deal), ISR +6% (cont volatility), FXCM +4.9% (news Friday afternoon that U.S. & U.K subsidiaries agreed to assume the vast majority of margin forex accounts of CitiFX Pro from Citibank N.A), FOLD +4.9% (confirms that the EMA CHMP has granted Accelerated Assessment for the co's Migalastat HCl monotherapy for Fabry patients), ONTY +3.3% (cont strength), AEGR +3.1% (announces it has achieved the primary endpoint in its Phase III Study of Lomitapide, to treat Homozygous Familial Hypercholesterolemia), PBY +1.8% (Glenhill Advisors discloses 7.0% active stake in 13D filing; to engage in dialogue with co), FEYE +1.6% (favorable commentary on Friday's Mad Money), BLDP +1.4% (receives order for breakthrough technology solutions project with Nisshinbo), JASO +1% (JA Solar and Essel Infraprojects sign MOU to establish a solar cell and module manufacturing facility with 500MW production capacity)
Analyst comments: CTRP +4.3% (target raised to $122 from $80 at Summit Research), BPMC +3.5% (initiated with an Outperform at Cowen), PRTY +1.9% (initiated with a Overweight at Morgan Stanley, initiated with a Overweight at JP Morgan, among others), MRVL +1.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley), LB +1.9% (added to Conviction Buy List at Goldman), BLUE +1.5% (target raised to $213 from $186 at Piper Jaffray), BSM +1.2% (initiated with an Overweight at Barclays), CEO +1.1% (upgraded to Neutral from Underweight at JP Morgan), PANW +1% (target raised to $175 at RBC Capital Mkts), EVA +0.9% (initiated with a Buy at Goldman, among others
)